Literature DB >> 34272691

Irreversible Enzyme Inhibition Kinetics and Drug-Drug Interactions.

Michael Mohutsky1, Stephen D Hall2.   

Abstract

This chapter describes the types of irreversible inhibition of drug-metabolizing enzymes and the methods commonly employed to quantify the irreversible inhibition and subsequently predict the extent and time course of clinically important drug-drug interactions.
© 2021. Springer Science+Business Media, LLC, part of Springer Nature.

Keywords:  Drug–drug interaction; Enzyme inactivation; Heme; IC50 shift; Mechanism-based inhibition; Metabolite intermediate complex; Suicide inhibition; Time-dependent inhibition

Year:  2021        PMID： 34272691     DOI： 10.1007/978-1-0716-1554-6_3

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN： 1064-3745


  106 in total

1.  Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites.

Authors:  D Sutton; A M Butler; L Nadin; M Murray
Journal:  J Pharmacol Exp Ther       Date:  1997-07       Impact factor: 4.030

2.  Comparative use of isolated hepatocytes and hepatic microsomes for cytochrome P450 inhibition studies: transporter-enzyme interplay.

Authors:  Hayley S Brown; Alison J Wilby; Jane Alder; J Brian Houston
Journal:  Drug Metab Dispos       Date:  2010-09-16       Impact factor: 3.922

3.  Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.

Authors:  Rick Greupink; Marieke Schreurs; Marina S Benne; Maarten T Huisman; Frans G M Russel
Journal:  Eur J Pharm Sci       Date:  2013-06-24       Impact factor: 4.384

4.  Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation.

Authors:  D R Jones; J C Gorski; M A Hamman; B S Mayhew; S Rider; S D Hall
Journal:  J Pharmacol Exp Ther       Date:  1999-09       Impact factor: 4.030

5.  The interaction of diltiazem with simvastatin.

Authors:  O Mousa; D C Brater; K J Sunblad; S D Hall
Journal:  Clin Pharmacol Ther       Date:  2000-03       Impact factor: 6.875

6.  The Impact of the Hepatocyte-to-Plasma pH Gradient on the Prediction of Hepatic Clearance and Drug-Drug Interactions for CYP2C9 and CYP3A4 Substrates.

Authors:  Luc R A Rougée; Michael A Mohutsky; David W Bedwell; Kenneth J Ruterbories; Stephen D Hall
Journal:  Drug Metab Dispos       Date:  2017-07-05       Impact factor: 3.922

7.  Inhibition of hepatic microsomal drug metabolism by the calcium channel blockers diltiazem and verapamil.

Authors:  K W Renton
Journal:  Biochem Pharmacol       Date:  1985-07-15       Impact factor: 5.858

8.  Prediction of the effect of erythromycin, diltiazem, and their metabolites, alone and in combination, on CYP3A4 inhibition.

Authors:  Xin Zhang; David R Jones; Stephen D Hall
Journal:  Drug Metab Dispos       Date:  2008-10-14       Impact factor: 3.922

9.  Semiphysiologically based pharmacokinetic models for the inhibition of midazolam clearance by diltiazem and its major metabolite.

Authors:  Xin Zhang; Sara K Quinney; J Christopher Gorski; David R Jones; Stephen D Hall
Journal:  Drug Metab Dispos       Date:  2009-05-06       Impact factor: 3.922

10.  In vitro forecasting of drugs which may interfere with the biotransformation of midazolam.

Authors:  M P Gascon; P Dayer
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953
View more
  1 in total

1.  Midazolam as a Probe for Heterotropic Drug-Drug Interactions Mediated by CYP3A4.

Authors:  Ilia G Denisov; Yelena V Grinkova; Mark A McLean; Tyler Camp; Stephen G Sligar
Journal:  Biomolecules       Date:  2022-06-20
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.